Loading...
Policy governs coverage and medical necessity of plasma homocysteine testing for screening, evaluation, and management of cardiovascular disease (CVD) and venous thromboembolic (VTE) disorders for BCBSRI Medicare Advantage and Commercial products. It states testing is not covered/ not medically necessary given evidence that lowering homocysteine does not improve outcomes.
No material clinical/coverage changes
Policy governs coverage and medical necessity of plasma homocysteine testing for screening, evaluation, and management of cardiovascular disease (CVD) and venous thromboembolic (VTE) disorders for BCBSRI Medicare Advantage and Commercial products. Measurement of plasma homocysteine is not covered for Medicare Advantage Plans and not medically necessary for Commercial Products. Effective date: 2024-01-01. Status: CURRENT (policy last reviewed 2024-01-17).
Policy Statement - Coverage Determination
Measurement of plasma homocysteine is not covered / not medically necessary for the following populations and indications:
ALL of the following
Indications
| No codes listed |
Prior authorization not applicable
Policy states prior authorization is not applicable for homocysteine testing; laboratories are not allowed to obtain authorization or participate on behalf of ordering physician; only ordering physician may be involved in authorization/appeal processes. If a laboratory provides a laboratory service that has not been authorized, the service will be denied as the financial liability of the participating laboratory and may not be billed to the member.
Authorization/appeal process responsibility
Only the ordering physician shall be involved in authorization, appeal, or other administrative processes related to authorization/medical necessity; use of laboratory representatives or third parties to obtain authorization is a violation and may result in termination from the BCBSRI provider network.
Plasma homocysteine has been extensively studied as a risk marker for CVD and VTE and as a target for folate/B‑vitamin lowering therapy. Although observational studies suggested an association between elevated homocysteine and vascular events, randomized controlled trials and meta‑analyses consistently demonstrate that homocysteine‑lowering interventions do not reduce major cardiovascular events and do not reliably reduce VTE risk. Given this large body of evidence, routine homocysteine testing is unlikely to improve health outcomes.
| Source | Finding |
|---|---|
| RCTs/meta-analyses | Homocysteine-lowering treatment does not consistently reduce major cardiovascular events; evidence insufficient to show net health outcome improvement |
| Cochrane finding | Some reduction in stroke risk reported but considered weak and of uncertain clinical significance |
Plasma total homocysteine: Sum of homocysteine and its oxidized forms measured in blood.
Claim denial if unauthorized laboratory obtains service
If a laboratory provides a laboratory service that has not been authorized, the service will be denied as the financial liability of the participating laboratory and may not be billed to the member.